Antisense oligonucleotides for modulating htra1 expression

Abstract

The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.

1 . (canceled) 
     
     
         2 . A method for treating macular degeneration or diabetic retinopathy, the method comprising intraocular administration of an oligonucleotide of 10-30 nucleotides in length which is complementary to SEQ ID NO: 113 to a patient suffering from or susceptible to macular degeneration or diabetic retinopathy 
     
     
         3 . The method of  claim 2 , wherein the patient is suffering from macular degeneration. 
     
     
         4 . The method of  claim 3 , wherein the macular degeneration is selected from the group consisting of: wet dry age-related macular degeneration (wAMD), dry age-related macular degeneration (dAMD), geographic atrophy, early age-related macular degeneration, and intermediate age-related macular degeneration. 
     
     
         5 . The method of  claim 2 , wherein the oligonucleotide has a sequence selected from: TTCTATCTACGCATTG (SEQ ID NO: 67), CTTCTTCTATCTACGCAT (SEQ ID NO: 73), and TACTTTAATAGCTCAA (SEQ ID NO: 86). 
     
     
         6 . A single-strand oligonucleotide of 10-30 nucleotides in length which is complementary to SEQ ID NO: 113 and includes a least one locked nucleic acids (LNA). 
     
     
         7 . The oligonucleotide of  claim 5 , wherein the oligonucleotide has a sequence selected from: TTCTATCTACGCATTG (SEQ ID NO: 67), CTTCTTCTATCTACGCAT (SEQ ID NO: 73), and TACTTTAATAGCTCAA (SEQ ID NO: 86).